Aclaris Therapeutics Inc Financials
Aclaris Therapeutics Inc (ACRS) reported $8.2M in revenue over the twelve months to Jun 30, 2026, down 51.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Aclaris operates as a development-stage biotech: shrinking commercial revenue sits beside heavy R&D and recurring dependence on financing.
R&D spending reached$52.6M against$7.8M of revenue in FY2025, so the economics remain investment-led rather than sales-funded. Even with a73.3% gross margin, operating cash flow was-$47.1M , showing that product-level gross profit is currently overwhelmed by development spending.
Revenue fell from
Reported liquidity equals 38.6 months of the latest annual outflow, while the current ratio is 3.4x; near-term obligations are therefore not the central constraint in these figures. The financing pattern is less self-sustaining: FY2024 brought
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Aclaris Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aclaris Therapeutics Inc scores -0.21, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($884.7M) relative to total liabilities ($57.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aclaris Therapeutics Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Aclaris Therapeutics Inc reported a net loss of $64.9M while operations used $47.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Aclaris Therapeutics Inc generated $7.8M in revenue in fiscal year 2025. This represents a decrease of 58.2% from the prior year.
Aclaris Therapeutics Inc's EBITDA was -$75.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.2% from the prior year.
Aclaris Therapeutics Inc reported -$64.9M in net income in fiscal year 2025. This represents an increase of 50.8% from the prior year.
Aclaris Therapeutics Inc earned -$0.53 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Aclaris Therapeutics Inc recorded an outflow of $47.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 133.8% from the prior year.
Aclaris Therapeutics Inc held $20.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Aclaris Therapeutics Inc's gross margin was 73.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 11.8 percentage points from the prior year.
Aclaris Therapeutics Inc's ROE was -63.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 21.9 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Aclaris Therapeutics Inc invested $52.6M in research and development in fiscal year 2025. This represents an increase of 56.7% from the prior year.
Aclaris Therapeutics Inc invested $111K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 8.3% from the prior year.
Not reported for fiscal year 2025.
ACRS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M-18.4% | $2.0M+54.1% | $1.3M-60.7% | $3.3M+85.6% | $1.8M+22.1% | $1.5M-84.2% | $9.2M+111.9% | $4.3M |
| Cost of Revenue | $218K-44.8% | $395K-25.8% | $532K-1.1% | $538K+4.5% | $515K+1.8% | $506K-28.2% | $705K+7.8% | $654K |
| Gross Profit | $1.4M-11.9% | $1.6M+109.8% | $763K-72.4% | $2.8M+118.8% | $1.3M+33.0% | $949K-88.8% | $8.5M+130.4% | $3.7M |
| R&D Expenses | $18.1M+15.4% | $15.7M-5.6% | $16.6M+27.3% | $13.0M+13.8% | $11.4M-1.2% | $11.6M+28.3% | $9.0M+51.5% | $6.0M |
| SG&A Expenses | $6.0M-10.3% | $6.7M+20.9% | $5.6M+14.5% | $4.9M-9.6% | $5.4M-12.3% | $6.1M+23.9% | $5.0M-12.4% | $5.7M |
| Operating Income | -$24.2M-9.2% | -$22.2M+2.4% | -$22.7M-32.6% | -$17.1M+6.8% | -$18.4M-1.8% | -$18.1M+81.9% | -$99.7M-851.9% | -$10.5M |
| Net Income | -$21.5M-8.5% | -$19.8M-0.1% | -$19.8M-35.5% | -$14.6M+5.3% | -$15.4M-2.3% | -$15.1M+84.4% | -$96.6M-1172.8% | -$7.6M |
| EPS (Diluted) | -$0.150.0% | -$0.15+6.3% | -$0.16-33.3% | -$0.12+7.7% | -$0.13-8.3% | -$0.12 | -$1.21-1000.0% | -$0.11 |
Not reported in any period shown, so not listed: Interest Expense, Income Tax.
ACRS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $179.7M-9.6% | $198.7M+23.8% | $160.5M-8.6% | $175.5M-7.2% | $189.1M-4.5% | $198.1M-10.1% | $220.3M+20.8% | $182.4M |
| Current Assets | $97.8M-11.3% | $110.2M+14.4% | $96.3M-4.3% | $100.6M-3.5% | $104.2M-4.2% | $108.8M-13.6% | $126.0M-4.8% | $132.3M |
| Cash & Equivalents | $19.2M-33.1% | $28.7M+43.6% | $20.0M-21.0% | $25.3M-0.6% | $25.4M-16.3% | $30.4M+23.6% | $24.6M-48.4% | $47.7M |
| Accounts Receivable | N/A | N/A | N/A | N/A | $194K-22.4% | $250K-21.4% | $318K-7.3% | $343K |
| Total Liabilities | $55.1M+0.1% | $55.1M-4.0% | $57.4M+3.5% | $55.4M-3.4% | $57.4M+6.3% | $54.0M-16.6% | $64.8M+24.0% | $52.2M |
| Current Liabilities | $28.2M+3.2% | $27.4M-4.5% | $28.6M+11.8% | $25.6M-4.5% | $26.8M+24.8% | $21.5M-31.9% | $31.6M+67.9% | $18.8M |
| Total Equity | $124.6M-13.3% | $143.6M+39.4% | $103.1M-14.2% | $120.1M-8.8% | $131.7M-8.6% | $144.1M-7.4% | $155.6M+19.5% | $130.2M |
| Retained Earnings | -$1.0B-2.2% | -$987.6M-2.0% | -$967.8M-2.1% | -$948.0M-1.6% | -$933.4M-1.7% | -$917.9M-1.7% | -$902.9M-12.0% | -$806.3M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
ACRS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.8M-9.4% | -$18.1M-38.2% | -$13.1M-20.1% | -$10.9M-9.4% | -$10.0M+23.5% | -$13.1M-46.1% | -$8.9M-140.6% | $22.0M |
| Capital Expenditures | $58K+346.2% | $13K-45.8% | $24K+4.3% | $23K+9.5% | $21K-51.2% | $43K | $0 | $0 |
| Free Cash Flow | -$19.9M-9.6% | -$18.2M-38.1% | -$13.2M-20.1% | -$11.0M-9.4% | -$10.0M+23.6% | -$13.1M-46.6% | -$8.9M-140.6% | $22.0M |
| Investing Cash Flow | $10.3M+133.2% | -$30.9M-398.3% | $10.4M-25.0% | $13.8M+174.0% | $5.0M-73.6% | $19.1M+121.5% | -$88.7M-3274.3% | $2.8M |
| Financing Cash Flow | $91K-99.8% | $57.8M+2380.2% | -$2.5M+16.8% | -$3.0M-33722.2% | -$9K+96.7% | -$275K-100.4% | $74.6M+338900.0% | $22K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ACRS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.6%+6.4pp | 80.2%+21.3pp | 58.9%-24.8pp | 83.7%+12.7pp | 71.0%+5.8pp | 65.2%-27.1pp | 92.3%+7.4pp | 85.0% |
| Operating Margin | -1487.9% | -1111.8% | -1755.5% | -519.8% | -1035.9% | -1242.9% | -1082.3% | -240.9% |
| Net Margin | -1320.1% | -993.2% | -1528.6% | -443.0% | -868.3% | -1036.8% | -1048.3% | -174.6% |
| Return on Equity | -17.3%-3.5pp | -13.8%+5.4pp | -19.2%-7.0pp | -12.2%-0.5pp | -11.7%-1.2pp | -10.5%+51.6pp | -62.1%-56.2pp | -5.8% |
| Return on Assets | -12.0%-2.0pp | -10.0%+2.4pp | -12.3%-4.0pp | -8.3%-0.2pp | -8.2%-0.5pp | -7.6%+36.2pp | -43.8%-39.7pp | -4.2% |
| Current Ratio | 3.46-0.6x | 4.03+0.7x | 3.36-0.6x | 3.920.0x | 3.88-1.2x | 5.06+1.1x | 3.99-3.0x | 7.03 |
| Debt-to-Equity | 0.44+0.1x | 0.38-0.2x | 0.56+0.1x | 0.460.0x | 0.44+0.1x | 0.380.0x | 0.420.0x | 0.40 |
| FCF Margin | -1221.9% | -909.9% | -1015.8% | -332.1% | -563.5% | -900.3% | -97.0% | 506.2% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Aclaris Therapeutics Inc Ranks
Frequently Asked Questions
What is Aclaris Therapeutics Inc's annual revenue?
Aclaris Therapeutics Inc (ACRS) reported $7.8M in total revenue for fiscal year 2025. This represents a -58.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aclaris Therapeutics Inc's revenue growing?
Aclaris Therapeutics Inc (ACRS) revenue declined by 58.2% year-over-year, from $18.7M to $7.8M in fiscal year 2025.
Is Aclaris Therapeutics Inc profitable?
No, Aclaris Therapeutics Inc (ACRS) reported a net income of -$64.9M in fiscal year 2025.
What is Aclaris Therapeutics Inc's EBITDA?
Aclaris Therapeutics Inc (ACRS) had EBITDA of -$75.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aclaris Therapeutics Inc's gross margin?
Aclaris Therapeutics Inc (ACRS) had a gross margin of 73.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Aclaris Therapeutics Inc's return on equity (ROE)?
Aclaris Therapeutics Inc (ACRS) has a return on equity of -63.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aclaris Therapeutics Inc's free cash flow?
Aclaris Therapeutics Inc (ACRS) recorded an outflow of $47.2M in free cash flow during fiscal year 2025. This represents a -133.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aclaris Therapeutics Inc's operating cash flow?
Aclaris Therapeutics Inc (ACRS) recorded an outflow of $47.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Aclaris Therapeutics Inc's total assets?
Aclaris Therapeutics Inc (ACRS) had $160.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Aclaris Therapeutics Inc's capital expenditures?
Aclaris Therapeutics Inc (ACRS) invested $111K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Aclaris Therapeutics Inc spend on research and development?
Aclaris Therapeutics Inc (ACRS) invested $52.6M in research and development during fiscal year 2025.
What is Aclaris Therapeutics Inc's current ratio?
Aclaris Therapeutics Inc (ACRS) had a current ratio of 3.36 as of fiscal year 2025, which is generally considered healthy.
What is Aclaris Therapeutics Inc's debt-to-equity ratio?
Aclaris Therapeutics Inc (ACRS) had a debt-to-equity ratio of 0.56 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aclaris Therapeutics Inc's return on assets (ROA)?
Aclaris Therapeutics Inc (ACRS) had a return on assets of -40.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Aclaris Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Aclaris Therapeutics Inc (ACRS) held $151.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $47.1M over that year. Dividing the one by the other, the reported balance equals about 39 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Aclaris Therapeutics Inc's Altman Z-Score?
Aclaris Therapeutics Inc (ACRS) has an Altman Z-Score of -0.21, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aclaris Therapeutics Inc's Piotroski F-Score?
Aclaris Therapeutics Inc (ACRS) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aclaris Therapeutics Inc's earnings high quality?
Aclaris Therapeutics Inc (ACRS) reported a net loss of $64.9M while operations used $47.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Aclaris Therapeutics Inc?
Aclaris Therapeutics Inc (ACRS) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.